Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VP-315

Other · developed by Verrica Pharmaceuticals

Phase 2 Most advanced trial (none active)
VRCA Developer
1 Registered trials

What is VP-315?

VP-315 is an agent administered by intratumor injection into a single target lesion, with dosing schedules of 2 to 8 mg daily over consecutive days. It is studied in basal cell carcinoma and other skin cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Verrica Pharmaceuticals Inc. (VRCA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05188729 Phase 2 Basal Cell Carcinoma Completed VRCA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Basal Cell CarcinomaCancer of the SkinCancer of the Skin, Basal CellCarcinomaSkin Cancer

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VRCA page.

Follow VRCA, the company behind VP-315

See VRCA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRCA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.